$2.17
0.11 (-4.82%)
Last updated: Apr 16, 2026 00:53
Fundamentals Overview
Allogene Therapeutics, Inc. is in the middle of its 52-week range with moderate valuation, trending downward today.
Valuation moderate
Risk (Beta)
0.54 — lower vol
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
3M vs S&P 500: +29.3% · 3M vs Healthcare sector: +36%
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: C-. Recent institutional grades: mixed. Current institutional positions: Buy: 14, Hold: 1, Market Outperform: 2, Market Perform: 1, Neutral: 1, Outperform: 7, Overweight: 3, Underweight: 1.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $-0.12; current price is $2.17. That’s a -105.4% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | N/A |
| PEG (TTM) | N/A |
| P/B (TTM) | 1.64 |
| P/S (TTM) | N/A |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 7.93 |
| Quick Ratio (TTM) | 7.93 |
| Cash Ratio (TTM) | 1.59 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | 0% |
| Gross margin (TTM) | 0% |
| Operating margin (TTM) | 0% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for ALLO.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Piper Sandler | maintain | Overweight | Overweight | 2026-03-13 |
| Canaccord Genuity | maintain | Buy | Buy | 2026-03-13 |
| Citizens | upgrade | Market Perform | Market Outperform | 2026-01-09 |
| JP Morgan | downgrade | Neutral | Underweight | 2025-10-10 |
| JP Morgan | downgrade | Overweight | Neutral | 2025-08-04 |
| JMP Securities | maintain | Market Perform | Market Perform | 2025-08-04 |
| Oppenheimer | maintain | Outperform | Outperform | 2025-08-01 |
| Citigroup | maintain | Buy | Buy | 2025-05-15 |
| Piper Sandler | maintain | Overweight | Overweight | 2025-05-14 |
| RBC Capital | maintain | Outperform | Outperform | 2025-05-14 |
| Baird | maintain | Outperform | Outperform | 2025-05-14 |
| Oppenheimer | maintain | Outperform | Outperform | 2025-05-14 |
| Truist Securities | maintain | Buy | Buy | 2025-05-14 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-03-19 |
| Canaccord Genuity | maintain | Buy | Buy | 2025-03-14 |
| RBC Capital | maintain | Outperform | Outperform | 2025-03-14 |
| Citizens Capital Markets | upgrade | Market Perform | Market Outperform | 2025-03-14 |
| Piper Sandler | maintain | Overweight | Overweight | 2024-11-14 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-11-08 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-10-30 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-08-15 |
| Truist Securities | maintain | Buy | Buy | 2024-08-09 |
| Citigroup | maintain | Buy | Buy | 2024-08-09 |
| Canaccord Genuity | maintain | Buy | Buy | 2024-08-08 |
| Oppenheimer | maintain | Outperform | Outperform | 2024-05-21 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-05-16 |
| Truist Securities | maintain | Buy | Buy | 2024-05-15 |
| Stifel | maintain | Hold | Hold | 2024-05-14 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2024-03-19 |
| RBC Capital | maintain | Outperform | Outperform | 2024-03-15 |